Overweight Clinical Trials in La Mesa, California

4 studies are recruiting for overweight in La Mesa, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

    The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

    Stage
    Phase 3
    Ages
    18 to 99
    Site
    Velocity Clinical Research Chula Vista, La Mesa, California
    Locations
    45 in total
    Run by
    Amgen

    See if you can join NCT07684144 on ClinicalTrials.gov

  2. A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

    The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    EndoTrials Center for Clinical Research, La Mesa, California
    Locations
    185 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07392190 on ClinicalTrials.gov

  3. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

    Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    AURORA-2 Clinical Site, La Mesa, California
    Locations
    135 in total
    Run by
    Ascletis Pharma (China) Co., Limited

    See if you can join NCT07743450 on ClinicalTrials.gov

  4. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

    Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight wit…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    AURORA-1 Clinical Site, La Mesa, California
    Locations
    122 in total
    Run by
    Ascletis Pharma (China) Co., Limited

    See if you can join NCT07743463 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.